CanBas Co., Ltd.
4575.TJPXHealthcareBiotechnology
Latest quote
¥795
−¥7.00 · -0.87%
Aug 24, 11:25 AM JST
4575.T company overview
Regular session · JST · Market data may be delayed.
Company profile
Company websiteCanBas Co., Ltd. is a biopharmaceutical company in the clinical stage, dedicated to discovering and developing new therapies for cancer patients. Its main investigational compounds include CBP501, a calmodulin-modulating peptide aimed at treating various cancers, and CBS9106, a reversible exportin-1 inhibitor currently in Phase I clinical trials for solid tumors. The company also engages in a strategic partnership with Stemline Therapeutics, Inc. Established in Numazu, Japan, in 2000, CanBas Co., Ltd. continues its work in oncology.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- JP
- CEO
- Takumi Kawabe
- Listed since
- Sep 17, 2009
- Employees
- 14
Market position
Day range
Current ¥795
¥784¥819
52-week range
Current ¥795
¥506¥1,558
- Open
- ¥798
- Previous close
- ¥802
- Volume
- 122K
- 0.58× average
- Average volume
- 209.84K
- Average daily volume
- Market cap
- 15.66B JPY
- Beta
- -0.82
- Market reference 1
- 50-day average
- ¥685.64
- +15.95% above average
- 200-day average
- ¥749.83
- +6.02% above average
4575.T peers
Continue in GoAI
Research 4575.Tresearch.disclaimer